Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Clinical trial NCT05456685 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05456685
Sponsor: AbbVie
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

High Grade Ovarian Cancer Primary Peritoneal Cancer Fallopian Tube Cancer

Start date: 2022-09-28
Primary completion: 2026-11-01
Enrollment: 125

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.